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of the significant possibility of negative histological findings 
following salvage surgery. 
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Purpose/Objective: To investigate the prognostic impact of 
adjuvant chemotherapy in patients with high-risk 
nasopharyngeal carcinoma (NPC).  
Materials and Methods: Our definition of high-risk NPC 
included patients with 1) neck node > 6 cm; 2) 
supraclavicular node metastasis; 3) skull base 
destruction/intracranial invasion plus multiple nodes 
metastasis; or 4) multiple neck nodes metastasis with one of 
nodal size > 4 cm. Four hundreds and three high-risk NPC 
patients completed full-course of concurrent 
chemoradiotherapy or neoadjuvant chemotherapy plus 
radiotherapy were retrospectively reviewed. Post-radiation 
adjuvant chemotherapy with oral tegafur-uracil (two capsules 
per day) for 12 months was administered to 154 patients, the 
remaining 249 patients did not receive any adjuvant 
chemotherapy. We analyzed the treatment outcome between 
patients with and without adjuvant chemotherapy. 
Results: Baseline patient characteristics at diagnosis (age, 
sex, pathological type, performance status, T-classification, 
N-classification) and previous treatment modality were 
comparable in both arms. After a median follow-up of 72 
months for surviving patients, 31.8% (49/154) and 42.2% 
(105/249) in patients with and without adjuvant 
chemotherapy developed tumor relapse respectively. The 5-
year distant metastasis and locoregional failure-free survival 
rates for patients with and without adjuvant chemotherapy 
were 82.1% vs. 68.5% (P=0.0018) and 84.3% vs. 82.6% 
(P=0.7848), respectively. Patients with adjuvant 
chemotherapy had better overall survival than those without 
adjuvant chemotherapy (5-year rates, 80.5% vs. 66.3%, 
P=0.0001). 
Conclusions: Adjuvant chemotherapy can reduce distant 
failure and improve overall survival in high-risk NPC patients 
after curative concurrent chemoradiotherapy or neoadjuvant 
chemotherapy + radiotherapy.  
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Purpose/Objective: In many of the previous studies of the 
clinical outcomes of radiotherapy (RT) alone, an interruption 
of RT was found to be a significant predictor of the local 
control. The efficacy of concurrent chemoradiotherapy 
(CCRT) using hyperfractionated RT was confirmed in a meta-
analysis. Hyperfractionated RT has resulted in increased 
severe acute complications. However, there have been no 
reports that have evaluated the prognostic impact of the 
overall treatment time or completion rate of concurrent 
chemotherapy in patients treated with CCRT using 
hyperfractionated RT. The purpose of this study was 
therefore to investigate the prognostic impact of the overall 
treatment time and completion rates of chemotherapy in 
patients with squamous cell carcinoma of the head and neck 
cancer (SCCHN) who were treated with CCRT using 
hyperfractionated RT. 
Materials and Methods: Sixty-nine consecutive patients with 
SCCHN were initially treated with definitive CCRT and were 
retrospectively analyzed. All 69 patients were treated with 
CCRT using hyperfractionated RT of 72 Gy in 60 fractions and 
daily carboplatin (25 mg/m2). The patients treated with 
other chemotherapeutic regimens or induction chemotherapy 
were excluded. Carboplatin was planned to be administered 
as an intravenous bolus immediately before the first daily 
fraction at a dose of 25 mg/m2 on every treatment day. On 
the intermission days of the hyperfractionated RT, 
carboplatin was not prescribed. After the intermission, CCRT 
using hyperfractionated RT plus daily carboplatin or 
hyperfractionated RT alone was resumed. Univariate analyses 
were performed using several factors including overall 
treatment days and days of RT without carboplatin to 
identify prognostic factors for the survival rates. 
Results: Median follow-up time was 46 months. The overall 
treatment days were as follows; 39-42 (n=16), 43-48 (n=29), 
49-54 (n=9) and ≥55 (n=15), and the days of RT without 
carboplatin; 0 (n=27), 1-5 (n=13), 6-10 (n=13) and ≥7 (n=16). 
The overall treatment time (≤48 days vs ≥49 days) was a 
significant prognostic factor for the local control, disease-
free survival and overall survival rates. The completion rate 
of chemotherapy, as the number of days of RT without 
carboplatin, was not a significant factor affecting any of the 
survival rates. The clinical stage was a significant factor 
associated with the LC, DFS DMFS and OS. The T stage was 
also a significant predictor of the LC, DFS and OS. 
Conclusions: This study demonstrated that the overall 
treatment time influenced the clinical outcomes in SCCHN 
patients treated with concurrent CCRT using 
hyperfractionated RT and daily carboplatin, while the impact 
of the completion rates of daily carboplatin was limited. 
Therefore, when acute toxicities caused a treatment 
interruption, hyperfractionated RT alone should be resumed 
as soon as possible. 
   
 
 
 
